Marina Biotech (OTCMKTS:MRNA)‘s stock had its “buy” rating reissued by stock analysts at Oppenheimer in a note issued to investors on Tuesday.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC initiated coverage on shares of Marina Biotech in a research report on Wednesday, January 2nd. They set a “buy” rating and a $28.00 target price on the stock. Bank of America initiated coverage on shares of Marina Biotech in a research report on Wednesday, January 2nd. They set a “buy” rating and a $20.00 target price on the stock. Goldman Sachs Group initiated coverage on shares of Marina Biotech in a research report on Wednesday, January 2nd. They set a “buy” rating and a $25.00 target price on the stock. JPMorgan Chase & Co. reissued a “buy” rating on shares of Marina Biotech in a research report on Thursday, January 10th. Finally, Morgan Stanley started coverage on shares of Marina Biotech in a research report on Wednesday, January 2nd. They set an “overweight” rating and a $29.00 target price on the stock. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. Marina Biotech currently has an average rating of “Buy” and a consensus target price of $24.38.

Shares of MRNA stock opened at $20.35 on Tuesday. Marina Biotech has a fifty-two week low of $13.03 and a fifty-two week high of $24.40.

A hedge fund recently bought a new stake in Marina Biotech stock. Essex Investment Management Co. LLC purchased a new position in shares of Marina Biotech, Inc. (OTCMKTS:MRNA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,551 shares of the biotechnology company’s stock, valued at approximately $146,000.

About Marina Biotech

Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.

Featured Article: The components of the Stochastic Momentum Index

Analyst Recommendations for Marina Biotech (OTCMKTS:MRNA)

Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.